Lucid Diagnostics Inc (LUCD)
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. Co. is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). Co.'s products include EsoGuard, and EsoCheck. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures.
| Company Name: |
Lucid Diagnostics Inc |
| Website: |
www.luciddx.com |
| Sector: |
Diagnostics |
| Number of ETFs Holding LUCD: |
2 |
| Total Market Value Held by ETFs: |
$975975 |
| Total Market Capitalization: |
$110.00M |
| % of Market Cap. Held by ETFs: |
0.89% |
|
|
April 20, 2025 • 1:53 AM Eastern
Strong Buy (3.67 out of 4)
64th percentile
|
|
Free LUCD Email Alerts:
